Nateglinide

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes.

Nateglinide

Fastic, Nateglinide, Starlix, Senaglinide, Starsis

Glinate, Natefine, Natelide, Natiz, NDS

(2R)-2-({hydroxy[(1r,4r)-4-(propan-2-yl)cyclohexyl]methylidene}amino)-3-phenylpropanoic acid

NA

NA

Oral: 60 to 120 mg 3 times/day, up to 180 mg 3 times/day if needed.

For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.

Upper respiratory tract infection; Dizziness; bronchitis; back pain; arthropathy; hypoglycaemia; flu-like symptoms; cough; accidental trauma; diarrhoea.

• Increased levels/effects with enzyme inhibitors (e.g. fluconazole).
• Increased hypoglycaemic effects with salicylates, MAOIs, nonselective β-blockers, alcohol, NSAIDs.
• Decreased levels/effects with enzyme inducers (e.g. rifampicin).
• Hypoglycaemic effects decreased with thiazide corticosteroids, diuretics, sympathomimetic agents and thyroid products.
• Absorption delayed with food. Hypoglycaemic effects may be increased with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, American ginseng, gymnema, marshmallow and stinging nettle.
• Levels/effects may be reduced with St. John's wort.

Diabetic ketoacidosis; IDDM. Lactation.

Store at 25°C (77°F).

Molecular weight

317.429

Molecular formula

C19H27NO3

CAS number

105816-04-4

Precautions

• Pregnancy.
• Severe renal impairment.
• Monitor glycaemic levels during periods of stress.